Low-dose methotrexate linked to increased adverse events in some
USA: Methotrexate is the most commonly used drug for systemic rheumatic diseases worldwide and the recommended first-line agent for rheumatoid arthritis. Despite decades of clinical use, few randomized controlled trials have studied adverse events associated with LD-MTX use.
Researchers from Brigham and Women's Hospital have found that low-dose methotrexate (LD-MTX) was associated with a small to a modest increase in the risk for some adverse events, including skin cancer and gastrointestinal, infectious, pulmonary, and hematologic effects in patients at risk for heart disease in a randomized double-blind, placebo-controlled trial. The results of the trial are published in Annals of Internal Medicine.
"Methotrexate is a cornerstone drug for a variety of inflammatory diseases, especially for rheumatoid arthritis," said Daniel Solomon, MD, MPH, a rheumatologist in the Division of Rheumatology, Inflammation and Immunology at the Brigham. "Over the decades, we've learned about the side effects but only from small studies. Questions for both physicians and patients have lingered about the drug's safety. Our study offers a detailed side-effect profile that I think will help us prescribe methotrexate in an informed way."
Solomon and his colleagues looked at data on 4,786 participants from CIRT who were randomized to receive low-dose methotrexate with folate or a placebo. Of 2,391 subjects who received methotrexate, 87 per cent experienced an adverse event of interest compared to 81.5 per cent of those who were randomized to placebo.
According to Solomon, the team's most surprising finding was a doubling of the risk of skin cancer for participants taking methotrexate (53 incidents of skin cancer versus 26 for placebo). This result may be particularly important because patients with psoriatic arthritis -- a form of arthritis that affects people with psoriasis -- are already at increased risk of skin cancer.
Gastrointestinal, infectious, pulmonary and hematologic adverse events were also elevated, but the increased risk was mild to moderate. As anticipated, the team also saw an increase in liver test abnormalities and five cases of cirrhosis in the methotrexate arm versus zero in the placebo arm. The authors note that CIRT participants did not have rheumatoid arthritis or other rheumatic diseases and it is possible, although unlikely, that adverse event rates may vary outside of the CIRT population.
"We now have real numbers we can share with patients when talking about side effects," said Solomon. "We definitely wouldn't suggest this drug is too dangerous to give. But having a clear side-effect profile allows us to give it with eyes wide open and better balances the risks and benefits of an age-old drug."
for further references log on to:
